KF

Kaniz Fatma

Active Director Director DIN 08287441
DIN 08287441 First appointment Nov 2018 Primary industry Trading
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Nov 2018
Shareholding value •••• Premium profile

About Kaniz Fatma

Data last updated:

Kaniz Fatma is a Director at Heross Pharma Private Limited (since 2018). The company operates in Trading. Heross Pharma Private Limited reported revenue of ₹42.7 Lakh (FY 2025).

DIN 08287441
Primary Designation Director
Industry Trading
First Appointment 27 Nov 2018
Oldest Company Age 7 yrs
Largest company Heross Pharma Private Limited · ₹42.7 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Heross Pharma Private Limited U51909DL2018PTC342177
Director27 Nov 20182018₹42.7 Lakh (FY 2025)Active

Board colleagues of Kaniz Fatma

NameDINCompanyDesignation
Farnaz Bano08287440Heross Pharma Private LimitedDirector

Directorship timeline

Open interactive timeline →
Heross Pharma Private Limited
Premium access

Shareholding and investment profile for Kaniz Fatma

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Kaniz Fatma

Kaniz Fatma currently holds 1 directorship: Heross Pharma Private Limited (Director, since 27 Nov 2018, revenue ₹42.7 Lakh (FY 2025)).

Kaniz Fatma was first appointed on 27 Nov 2018 as Director at Heross Pharma Private Limited.

The current boards of Kaniz Fatma's companies include Farnaz Bano (Heross Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available